公开(公告)号：US20210052554A1

公开(公告)日：2021-02-25

申请号：US17089064

申请日：2020-11-04

Applicant: Novartis AG

Inventor： Kamlesh Jagdis BALA ,  Andrew BREARLEY ,  James DALE ,  Anne-Marie EDWARDS ,  Mahbub AHMED ,  David PORTER ,  Robert Alexander PULZ ,  Lisa Ann ROONEY ,  David Andrew SANDHAM ,  Duncan SHAW ,  Nichola SMITH ,  Jessica Louise TAYLOR ,  Roger John TAYLOR ,  Thomas Josef Troxler ,  Joe WRIGGLESWORTH

IPC: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220340573A1

公开(公告)日：2022-10-27

申请号：US17805487

申请日：2022-06-06

Applicant: Novartis AG

Inventor： Kelly D. BOSS ,  Yi FAN ,  Alec Nathanson FLYER ,  Declan HARDY ,  Zhihong HUANG ,  Kathryn Taylor LINKENS ,  Jon Christopher LOREN ,  Fupeng MA ,  Valentina MOLTENI ,  Duncan SHAW ,  Jeffrey SMITH ,  Catherine Fooks SOLOVAY

IPC: C07D471/10 ,  A61P27/04 ,  C07D413/06 ,  C07D413/14 ,  C07D491/107

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.

公开(公告)号：US20240238305A1

公开(公告)日：2024-07-18

申请号：US18561444

申请日：2022-05-18

Applicant: Novartis AG

Inventor： Yi FAN ,  Declan HARDY ,  Zhihong HUANG ,  Jay Parthiban LAKSHMAN ,  Jon Christopher LOREN ,  Valentina MOLTENI ,  Sunil Kumar Mandala RAYABANDLA ,  Nuria Jimenez RIDRUEJO ,  Duncan SHAW ,  Jeffrey SMITH ,  Christopher Stephen TOWLER

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/10 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/44 ,  A61P27/04

CPC classification number: A61K31/5377 ,  A61K9/0048 ,  A61K9/10 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/44 ,  A61P27/04

Abstract: Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione and pharmaceutically acceptable salts thereof, processes for their production, and uses thereof, including in the treatment of ocular diseases and disorders such as dry eye disease and Meibomian gland dysfunction (MGD).

公开(公告)号：US20190381011A1

公开(公告)日：2019-12-19

申请号：US16230033

申请日：2018-12-21

Applicant: Novartis AG

Inventor： Kamlesh Jagdis BALA ,  Andrew BREARLEY ,  James DALE ,  Anne-Marie EDWARDS ,  Mahbub AHMED ,  David PORTER ,  Robert Alexander PULZ ,  Lisa Ann ROONEY ,  David Andrew SANDHAM ,  Duncan SHAW ,  Nichola SMITH ,  Jessica Louise TAYLOR ,  Roger John TAYLOR ,  Thomas Josef Troxler ,  Joe WRIGGLESWORTH

IPC: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20230301970A1

公开(公告)日：2023-09-28

申请号：US18317990

申请日：2023-05-16

Applicant: Novartis AG

Inventor： Kamlesh Jagdis BALA ,  Andrew BREARLEY ,  James DALE ,  Anne-Marie EDWARDS ,  Mahbub AHMED ,  David PORTER ,  Robert Alexander PULZ ,  Lisa Ann ROONEY ,  David Andrew SANDHAM ,  Duncan SHAW ,  Nichola SMITH ,  Jessica Louise TAYLOR ,  Roger John TAYLOR ,  Thomas Josef TROXLER-SCHWAB ,  Joe WRIGGLESWORTH

IPC: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

CPC classification number: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof;




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220064164A1

公开(公告)日：2022-03-03

申请号：US17101510

申请日：2020-11-23

Applicant: NOVARTIS AG

Inventor： Kelly D. BOSS ,  Yi FAN ,  Alec Nathanson FLYER ,  Declan HARDY ,  Zhihong HUANG ,  Kathryn Taylor LINKENS ,  Jon Christopher LOREN ,  Fupeng MA ,  Valentina MOLTENI ,  Duncan SHAW ,  Jeffrey SMITH ,  Catherine Fooks SOLOVAY

IPC: C07D471/10 ,  C07D413/14 ,  C07D413/06 ,  C07D491/107 ,  A61P27/04

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.

公开(公告)号：US20200268718A1

公开(公告)日：2020-08-27

申请号：US16874595

申请日：2020-05-14

Applicant: Novartis AG

Inventor： Kamlesh Jagdis BALA ,  Andrew BREARLEY ,  James DALE ,  Anne-Marie EDWARDS ,  Mahbub AHMED ,  David PORTER ,  Robert Alexander PULZ ,  Lisa Ann ROONEY ,  David Andrew SANDHAM ,  Duncan SHAW ,  Nichola SMITH ,  Jessica Louise TAYLOR ,  Roger John TAYLOR ,  Thomas Josef TROXLER ,  Joe WRIGGLESWORTH

IPC: A61K31/422 ,  C07D413/14 ,  A61K31/4155 ,  C07D413/12

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20170014388A1

公开(公告)日：2017-01-19

申请号：US15184730

申请日：2016-06-16

Applicant: Novartis AG

Inventor： Kamlesh Jagdis BALA ,  Andrew BREARLEY ,  James DALE ,  Anne-Marie EDWARDS ,  Mahbub AHMED ,  David PORTER ,  Robert Alexander PULZ ,  Lisa Ann ROONEY ,  David Andrew SANDHAM ,  Duncan SHAW ,  Nichola SMITH ,  Jessica Louise TAYLOR ,  Roger John TAYLOR ,  Thomas Josef Troxler ,  Joe WRIGGLESWORTH

IPC: A61K31/422

CPC classification number: A61K31/422 ,  A61K31/4155 ,  C07D413/12 ,  C07D413/14 ,  A61K2300/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。